NOVO — November 2023
-
Det er bla den store reduktion i inflammation fra semaglutid, der gør de har valgt at smide et ret stort beløb efter det. Jeg anser det som HIGH risk
-
Pre-market US 99,82...ikke så meget begejstring:-(
-
Bliver “pumpet” stille og roligt ned i minus, som den “plejer”
-
Medicinmystik: Hun døde kort efter
Ifølge Trish Websters mand døde hans kone, kort efter at hun have taget Ozempic i en periode. Novo Nordisk afviser at tage stilling til den konkrete sag
Ekstra Bladet (ekstrabladet.dk)
-
Statnews.com og shortere på spil
-
13:12
Novo Nordisk oplyser, at udviklingsdirektør David Moore som led i sin ansættelsespakke har modtaget 18.636 aktier i medicinalkoncernen.Herefter har han solgt 8217 Novo-aktier for en samlet kursværdi af 5,8 mio. kr.
Novo-aktien handles mandag midt på dagen til 709,20 kr. efter en stigning på 2,5 pct.
.\˙ MarketWire
-
Citi analysts said the outlook for weight-loss drugs has been “turbocharged” by the data presented at the American Heart Association’s annual scientific meeting in Philadelphia.
-
“The datasets were enthusiastically received in packed auditoriums, with discussants hailing a certain paradigm change in treatment practice,” analysts led by Peter Verdult said. “Importantly from a commercial perspective, the greatest benefit was seen in younger patients and lower BMI ranges,” they added. They have a Buy rating on the stock with a target price of 815 Danish kroner, implying 15% upside to Monday’s price.
-
Enig Nohope. Novo skal da forfølge de muligheder der er. og AD i sig selv kan blive et giga marked idet der pt ikke rigtigt er nogle stoffer der giver ret meget effekt
-
Jeg tror de kommer til at øge udgifter til senfase studier mega max meget de kommende år. CagriSema bliver startet op i flere store forsøg. Uden at vide det, så gætter jeg på CagriSema har patent frem til noget i retningen af 2040
-
Bank of America analyst Geoff Meacham says the results of Novo's Select study support much broader insurance coverage of weight-loss drugs.
-
According to our (key opinion leaders), the Select results will be 'hard to ignore' and 'payers are going to have to go along' with treatment plus coverage, which speaks to the enthusiasm we felt throughout the conference," he said in a report.
-
Novo Skids — But These Weight-Loss Results Are 'Hard To Ignore'
Novo Nordisk stock fell Monday despite unveiling promising test results for weight-loss drugs and diabetes. Eli Lilly stock reversed higher.
Investor's Business Daily (www.investors.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind